アハメド・グラウコマのバルブインプラントにおけるミトミシンCは,手術の結果に影響します
Wei-Chun Lin1, Sen Yang1, Michelle R Hribar1
1Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd, Portland, OR 97239, USA.
Bioengineering (Basel, Switzerland)
|August 28, 2025
まとめ
ミトマイシンC (MMC) の補助注射は,眼内圧 (IOP) を低下させ,アハメド・グラウコマ・バルブ (AGV) 手術の短期的な結果を改善しました. しかし,これらの利益は長期にわたって維持されず,12ヶ月で有意な差はありませんでした.
科学分野:
- 眼科について
- 外科 革新
- グラウコマ 管理
背景:
- グローコマは 世界的に不可逆的な失明の 主な原因です
- アハメド・グラウコマ・バルブ (AGV) 植入は,グラウコマに対する一般的な手術です.
- ミトマイシンC (MMC) は,AGVの障害を防ぐ可能性のある抗線維剤です.
研究 の 目的:
- ミトミシンC (MMC) の追加注射によるAGV移植の外科的結果を評価する.
- AGVとMMCを併用した患者と,AGV単独で投与された患者のアウトカムを比較する.
- AGV手術におけるMMCの短期的および長期的有効性を評価する.
主な方法:
- 遡及的ケース・コントロール研究設計
- AGVのインプラントを施した142の目が含まれています.
- MMCを併用した50の目と,MMCを併用していない92の目との結果の比較
主要な成果:
- 手術後1,3,6ヶ月で,MMCを併用することで,眼内圧 (IOP) が有意に低下した.
- MMC群は短期的に (1~6ヶ月) より少量の緑内障薬を必要とした.
- IOPや薬剤使用の統計的に有意な差は12ヶ月で観察されなかった.
結論:
- 補助的なMMCは,AGV緑内障インプラントの短期的な手術結果を改善します.
- IOPと薬物の使用に対するMMCの効果は一時的なもので,長期的には持続しません.
- 暫定的な低血圧と関連しているが,添加MMCは長期的な合併症を引き起こさなかった.
関連する概念動画
Angle Closure Glaucoma: Treatment
669
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
669
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Open Angle Glaucoma: Treatment
557
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
557
Mitral Regurgitation III: Medical Management
28
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
28
Glaucoma: Overview
745
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
745


